Sarepta Therapeutics Statistics
Share Statistics
Sarepta Therapeutics has 95.52M shares outstanding. The number of shares has increased by 1.95% in one year.
| Shares Outstanding | 95.52M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.89% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 88.92M |
| Failed to Deliver (FTD) Shares | 6.84K |
| FTD / Avg. Volume | 0.71% |
Short Selling Information
The latest short interest is 5.60M, so 5.86% of the outstanding shares have been sold short.
| Short Interest | 5.60M |
| Short % of Shares Out | 5.86% |
| Short % of Float | 6.25% |
| Short Ratio (days to cover) | 7.15 |
Valuation Ratios
The PE ratio is -16.62 and the forward PE ratio is 10.08.
| PE Ratio | -16.62 |
| Forward PE | 10.08 |
| PS Ratio | 7.17 |
| Forward PS | 3.8 |
| PB Ratio | 10.37 |
| P/FCF Ratio | -15.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Sarepta Therapeutics Inc. has an Enterprise Value (EV) of 9.88B.
| EV / Earnings | -18.43 |
| EV / Sales | 7.95 |
| EV / EBITDA | -22.49 |
| EV / EBIT | -36.88 |
| EV / FCF | -16.79 |
Financial Position
The company has a current ratio of 3.95, with a Debt / Equity ratio of 1.46.
| Current Ratio | 3.95 |
| Quick Ratio | 3.45 |
| Debt / Equity | 1.46 |
| Total Debt / Capitalization | 59.37 |
| Cash Flow / Debt | -0.4 |
| Interest Coverage | -12.17 |
Financial Efficiency
Return on equity (ROE) is -0.62% and return on capital (ROIC) is -12.23%.
| Return on Equity (ROE) | -0.62% |
| Return on Assets (ROA) | -0.16% |
| Return on Capital (ROIC) | -12.23% |
| Revenue Per Employee | 946.22K |
| Profits Per Employee | -407.90K |
| Employee Count | 1.31K |
| Asset Turnover | 0.38 |
| Inventory Turnover | 0.47 |
Taxes
| Income Tax | 15.88M |
| Effective Tax Rate | -0.03 |
Stock Price Statistics
The stock price has increased by 32.89% in the last 52 weeks. The beta is 0.8, so Sarepta Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.8 |
| 52-Week Price Change | 32.89% |
| 50-Day Moving Average | 122.67 |
| 200-Day Moving Average | 129.71 |
| Relative Strength Index (RSI) | 51.27 |
| Average Volume (20 Days) | 957.04K |
Income Statement
In the last 12 months, Sarepta Therapeutics had revenue of $1.24B and earned -$535.98M in profits. Earnings per share was $-5.8.
| Revenue | 1.24B |
| Gross Profit | 1.09B |
| Operating Income | -267.82M |
| Net Income | -535.98M |
| EBITDA | -439.20M |
| EBIT | -267.82M |
| Earnings Per Share (EPS) | -5.8 |
Balance Sheet
The company has $428.43M in cash and $1.40B in debt, giving a net cash position of -$968.38M.
| Cash & Cash Equivalents | 428.43M |
| Total Debt | 1.40B |
| Net Cash | -968.38M |
| Retained Earnings | -4.45B |
| Total Assets | 3.60B |
| Working Capital | 1.99B |
Cash Flow
In the last 12 months, operating cash flow was -$500.99M and capital expenditures -$76.11M, giving a free cash flow of -$588.34M.
| Operating Cash Flow | -500.99M |
| Capital Expenditures | -76.11M |
| Free Cash Flow | -588.34M |
| FCF Per Share | -6.37 |
Margins
Gross margin is 87.91%, with operating and profit margins of -21.54% and -43.11%.
| Gross Margin | 87.91% |
| Operating Margin | -21.54% |
| Pretax Margin | -41.83% |
| Profit Margin | -43.11% |
| EBITDA Margin | -35.32% |
| EBIT Margin | -21.54% |
| FCF Margin | -47.32% |
Dividends & Yields
SRPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -4.69% |
| FCF Yield | -4.98% |
Analyst Forecast
The average price target for SRPT is $181, which is 46.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $181 |
| Price Target Difference | 46.5% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
Stock Splits
The last stock split was on Jul 12, 2012. It was a backward split with a ratio of 1:6.
| Last Split Date | Jul 12, 2012 |
| Split Type | backward |
| Split Ratio | 1:6 |
Scores
| Altman Z-Score | 2.54 |
| Piotroski F-Score | 4 |